Management of patients with multiple myeloma during the COVID-19 pandemic
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
A novel coronavirus of zoonotic origin emerged in China at the end of December 2019. The infection, named coronavirus disease 2019 (COVID-19), is now spreading worldwide. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus, which has a phylogenetic similarity to another known coronavirus, SARS-CoV-1, the causative agent of SARS responsible for a major epidemic in 2003. The contagious potential of this virus is proving to be very rapid and unpredictable. As of April 20, 2020, more than 2·4 million cases of COVID-19 have been confirmed resulting in more than 150?000 deaths worldwide. Mortality can be as high as 15% in older patients and those with comorbidities.1 The severity of COVID-19 is classified into four types: mild, ordinary, severe, and critical. In addition, approximately 18% of patients are estimated to have asymptomatic SARS-CoV-2 infection.2 At present, no treatment options have been approved in Europe, and no vaccine is available. Avoiding exposure by adhering to recommended hygiene procedures, isolation of infected people, and social distancing are the only prevention strategies recommended by the WHO.
The Lancet Haematology , article en libre accès, 2019